The double-blind multicenter phase 3 trials STEP 1, 3, 4, 5 were conducted in adults (mean age 46.247.3 years), mostly females, with obesity or overweight with 1 weight-related complication (mean BMI 37.838.4 kg/m 2 ) and aimed to demonstrate the superiority of semaglutide 2.4 mg over placebo in BW lowering at 68 or 104 24 weeks as an adjunct to diet and physical activity 23
Human plasma levels peak post-exercise, explaining its exercise in a bottle nickname
The product is manufactured at FDA-registered facilities under Current Good Manufacturing Practice (cGMP) regulations
So that's like your first 50 years of your life
However, conclusive evidence supporting these claims remains limited, and more extensive research is needed to substantiate these purported benefits comprehensively
Your clinician will advise you on appropriate monitoring and follow-up if a course of treatment is required